Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys

Parkinsonism and Related Disorders

Volumn 17, Issue 1, 2011, Pages 34-39

  Lieu, Christopher A ^a   Deogaonkar, Milind ^b   Bakay, Roy A E ^c   Subramanian, Thyagarajan ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Basal ganglia; Dopamine replacement therapy; Macaca mulatta; Movement disorders; Nigrostriatal degeneration

Indexed keywords

6 FLUORODOPA F 18; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; DOPA DECARBOXYLASE INHIBITOR; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOREOATHETOSIS; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DYSKINESIA; DYSTONIC DISORDER; FEMALE; NONHUMAN; OPTIMAL DRUG DOSE; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHESUS MONKEY; SINGLE DRUG DOSE; TREATMENT DURATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; CAROTID ARTERIES; CONDITIONING, OPERANT; CORPUS STRIATUM; DIHYDROXYPHENYLALANINE; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; DYSTONIA; FEMALE; INJECTIONS, INTRAVENOUS; LEVODOPA; MACACA MULATTA; MPTP POISONING; PARKINSON DISEASE, SECONDARY; PSYCHOMOTOR PERFORMANCE; RADIOPHARMACEUTICALS; SUBSTANTIA NIGRA;

EID: 78651100065     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2010.10.010     Document Type: Article

References (30)

1. Kumar N., Van Gerpen J.A., Bower J.H., Ahlskog J.E. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord 2005, 20:342-344.
2. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001, 344:710-719.
3. Mouradian M.M., Heuser I.J., Baronti F., Fabbrini G., Juncos J.L., Chase T.N. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989, 25:523-526.
4. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000, 290:767-773.
5. Collier T.J., Dung Ling Z., Carvey P.M., Fletcher-Turner A., Yurek D.M., Sladek J.R., et al. Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism. Exp Neurol 2005, 191(Suppl. 1):S60-S67.
6. Starr P.A., Wichmann T., van Horne C., Bakay R.A. Intranigral transplantation of fetal substantia nigra allograft in the hemiparkinsonian rhesus monkey. Cell Transplant 1999, 8:37-45.
7. Subramanian T., Emerich D.F., Bakay R.A., Hoffman J.M., Goodman M.M., Shoup T.M., et al. Polymer-encapsulated PC-12 cells demonstrate high-affinity uptake of dopamine in vitro and 18F-Dopa uptake and metabolism after intracerebral implantation in nonhuman primates. Cell Transplant 1997, 6:469-477.
8. Subramanian T., Lieu C.A., Guttalu K., Berg D. Detection of MPTP-induced substantia nigra hyperechogenicity in rhesus monkeys by transcranial ultrasound. Ultrasound Med Biol 2010, 36:604-609.
9. Soderstrom K., O'Malley J., Steece-Collier K., Kordower J.H. Neural repair strategies for Parkinson's disease: insights from primate models. Cell Transplant 2006, 15:251-265.
10. Emborg M.E. Nonhuman primate models of Parkinson's disease. ILAR J 2007, 48:339-355.
11. Mizuno Y. Simple gas chromatographic analysis of plasma dopa and dopamine. Clin Chim Acta 1977, 74:11-19.
12. Kurlan R., Kim M.H., Gash D.M. Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. Mov Disord 1991, 6:111-118.
13. Fass B., Butcher L.L. Evidence for a crossed nigrostriatal pathway in rats. Neurosci Lett 1981, 22:109-113.
14. Collingridge G.L. Electrophysiological evidence for the existence of crossed nigrostriatal fibers. Experientia 1982, 38:812-813.
15. Francois C., Percheron G., Yelnik J. Localization of nigrostriatal, nigrothalamic and nigrotectal neurons in ventricular coordinates in macaques. Neuroscience 1984, 13:61-76.
16. Oiwa Y., Eberling J.L., Nagy D., Pivirotto P., Emborg M.E., Bankiewicz K.S. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes. Front Biosci 2003, 8:a155-a166.
17. Papa S.M., Desimone R., Fiorani M., Oldfield E.H. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. Ann Neurol 1999, 46:732-738.
18. Liang L., DeLong M.R., Papa S.M. Inversion of dopamine responses in striatal medium spiny neurons and involuntary movements. J Neurosci 2008, 28:7537-7547.
19. Bankiewicz K.S., Daadi M., Pivirotto P., Bringas J., Sanftner L., Cunningham J., et al. Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys. Experiment Neurol 2006, 197:363-372.
20. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970, 24:485-493.
21. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59:401-415.
22. Fahn S. A new look at levodopa based on the ELLDOPA study. J Neural Transm Suppl 2006, 419-426.
23. Alves R.S., Barbosa E.R., Scaff M. Postvaccinal parkinsonism. Mov Disord 1992, 7:178-180.
24. Ruzicka E., Urgosik D., Jech R., Roth J., Vymazal J., Mecir P., et al. Hemiparkinsonism and levodopa-induced dyskinesias after focal nigral lesion. Mov Disord 2005, 20:759-762.
25. Clarke C.E., Boyce S., Robertson R.G., Sambrook M.A., Crossman A.R. Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci 1989, 90:307-314.
26. Pearce R.K., Heikkila M., Linden I.B., Jenner P. L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Psychopharmacology (Berl) 2001, 156:402-409.
27. Togasaki D.M., Tan L., Protell P., Di Monte D.A., Quik M., Langston J.W. Levodopa induces dyskinesias in normal squirrel monkeys. Ann Neurol 2001, 50:254-257.
28. Boyce S., Rupniak N.M., Steventon M.J., Iversen S.D. Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. Clin Neuropharmacol 1990, 13:448-458.
29. Pearce R.K., Jackson M., Smith L., Jenner P., Marsden C.D. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov Disord 1995, 10:731-740.
30. Emborg M.E., Carbon M., Holden J.E., During M.J., Ma Y., Tang C., et al. Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab 2007, 27:501-509.